simvastatin has been researched along with Endometrial Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, JS; Rodriguez, GC; Rosales, R; Thaete, LG; Turbov, J | 1 |
| Bae-Jump, VL; Gehrig, PA; Gilliam, TP; Han, X; Kim, K; Schointuch, MN; Stine, JE; Zhou, C | 1 |
2 other study(ies) available for simvastatin and Endometrial Neoplasms
| Article | Year |
|---|---|
Combination simvastatin and metformin synergistically inhibits endometrial cancer cell growth.
Topics: Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Drug Therapy, Combination; Endometrial Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Metformin; Simvastatin; TOR Serine-Threonine Kinases | 2019 |
Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer.
Topics: Apoptosis; Cell Adhesion; Cell Proliferation; Endometrial Neoplasms; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neoplasm Invasiveness; Neoplasm Metastasis; Simvastatin; Tumor Cells, Cultured | 2014 |